Skip to main content

Table 1 Clinical characteristics of HNSCC patients in TCGA and validation dataset

From: A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC

Variables

TCGA-HNSCC

(n = 491)

GSE65858

(n = 267)

GSE41613

(n = 97)

GSE686

(n = 71)

Age

  ≤ 60

244 (49.7%)

156 (58.4%)

50(51.55%)

49 (69.01%)

  > 60

247 (50.3%)

111 (41.6%)

47 (48.45%)

22 (30.99%)

Gender

 Female

131 (26.7%)

47 (17.6%)

31 (31.96%)

8 (11.27%)

 Male

360 (73.3%)

220 (82.4%)

66 (68.04%)

63 (88.73%)

Vital status

 Alive

280 (57.0%)

176 (65.9%)

46 (47.42%)

53 (74.65%)

 Dead

211 (43.0%)

91 (34.1%)

51 (52.58%)

18 (25.35%)

Histologic grade

 G1

54 (11.0%)

NA

NA

NA

 G2

293 (59.7%)

NA

NA

NA

 G3

120 (24.4%)

NA

NA

NA

 G4

7 (1.4%)

NA

NA

NA

 GX

17 (3.5%)

NA

NA

NA

Stage

 I

20 (4.1%)

17 (6.3%)

41 (42.27%)

0

 II

96 (19.5%)

37 (13.9%)

12 (16.90%)

 III

103 (21.0%)

37 (13.9%)

56 (57.73%)

18 (25.35%)

 IV

272 (55.4%)

176 (65.9%)

41 (57.75%)

T classification

 T1

34 (6.9%)

34 (12.7%)

NA

NA

 T2

147 (29.9%)

80 (30.0%)

NA

NA

 T3

132 (26.9%)

57 (21.3%)

NA

NA

 T4

178 (36.3%)

96 (36.0%)

NA

NA

N classification

 N0

240 (48.9%)

93 (34.8%)

NA

NA

 N1

79 (16.1%)

32 (12.0%)

NA

NA

 N2

155 (31.6%)

130 (48.7%)

NA

NA

 N3

9 (1.8%)

12 (4.5%)

NA

NA

 NX

8 (1.6%)

0

NA

NA

M classification

 M0

475 (96.7%)

261 (97.8%)

NA

NA

 M1

6 (1.2%)

6 (2.2%)

NA

NA

 MX

10 (2.0%)

0

NA

NA